Product category:
Chemicals and biochemicals
News Release from: MWG Biotech
Edited by the Laboratorytalk Editorial
Team on 27 July 2005
Licence to provide products and services
in RNAi
Many diseases are caused by the inappropriate activity of specific genes, so the ability to silence and regulate such genes selectively could provide a means to treat a wide range of human diseases
Alnylam Pharmaceuticals, a RNAi therapeutics company, has granted MWG Biotech, an established provider of synthetic nucleic acids, a non-exclusive licence to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells
This article was originally published on Laboratorytalk on 7 Apr 2005 at 8.00am (UK)
Related stories
Competent genome sequencing and annotation
Mutation analysis of production strains based on DNA sequencing and bioinformatic evaluation, by Dr Marcus Droege, Dr Dave Brett, Dr Jacqueline Weber-Lehmann, and Dr Kai Wilkens
View siRNA secondary structures before ordering
Said to be the only commercial on-line design tool that allows users to view the secondary structure of the mRNA target sequence at the siRNA site before placing an order
"This agreement with MWG, an international genomic solution provider, continues to highlight the value of the Alnylam-owned Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Vincent Miles, senior vice president, business development of Alnylam Pharmaceuticals.
"By leveraging our portfolio of leading IP, we are creating value today and for the future by amassing an increasing number of licence agreements with leading reagent and service providers.
"To date, eleven companies have taken licences for therapeutic or research product applications including six research product suppliers".
Further reading
siRNA in classical 21mer or new 27mer format
Small interfering RNA (siRNA) can be ordered in either the standard 21mer or in the new 27mer format, which has recently attracted scientific interest as it is assumed to provide higher efficiency
Predesigned exon-specific oligonucleotide primers
Exon locator and extractor for resequencing streamlines the process of determining exon/intron boundaries and designing PCR and sequencing primers
Catalogue 'is a must-have' for life scientists
MWG Biotech says its first comprehensive catalogue covering oligonucleotide synthesis, siRNA synthesis, and DNA sequencing is a definite 'must have' reference for life science researchers
"This license strengthens our siRNA offering and is part of our commitment to build a high quality presence in siRNA design and production", says Wolfgang Pieken, CEO of MWG Biotech.
RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes.
Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence and regulate such genes selectively through RNAi could provide a means to treat a wide range of human diseases.
The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002, as well as one of the top ten scientific advances of 2003.
Alnylam is a biopharmaceutical company seeking to develop and commercialise novel therapeutics based on RNA interference, or RNAi.
Growing from its foundation as the world's first company focused on RNAi therapeutics, it says its leadership in the field is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialisation of RNAi therapeutics.
Alnylam is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi to treat a broad range of diseases, including oncology, metabolic, and autoimmune diseases.
The company's global headquarters are in Cambridge, Massachusetts.
MWG Biotech is an international provider of DNA sequencing and DNA/siRNA synthesis products and services for academic and industrial research from production sites in Germany, the USA, and India.
With strong customer orientation, fast service and high quality products the company says it creates the platform for success in the life sciences today and for a better life tomorrow.
In its siRNA portfolio the company offers, in addition to a range of siRNA products, a series of advance siRNA design tools and other siRNA services.
• MWG Biotech: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
